Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-15T02:00:58.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Defining “True and Non-Misleading” for Pharmaceutical Promotion

Published online by Cambridge University Press:  01 January 2021

Spencer Phillips Hey  and
Aaron S. Kesselheim
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Information
Journal of Law, Medicine & Ethics , Volume 46 , Issue 2: Law and the Opioid Crisis: An Inter-Disciplinary Examination , Summer 2018 , pp. 552 - 554
Copyright
Copyright © American Society of Law, Medicine and Ethics 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Food and Drug Administration, Medical Product Communications That Are Consistent With FDA-Required Labeling—Questions And Answers, January 19, 2017, available at <https://www.federalregister.gov/documents/2017/01/19/2017-01012/medical-product-communications-that-are-consistent-with-the-food-and-drug-administration-required> (last visited May 24, 2018).+(last+visited+May+24,+2018).>Google Scholar
Food and Drug Administration, Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unap-proved Uses of Approved or Cleared Medical Products, January 19, 2017, available at <https://www.federalregister.gov/documents/2017/01/19/2017-01013/manufacturer-communications-regarding-unapproved-uses-of-approved-or-cleared-medical-products> (last visited May 24, 2018).+(last+visited+May+24,+2018).>Google Scholar
Robertson, C. and Kesselheim, A.S., “Regulating Off-Label Promotion—A Critical Test,” New England Journal of Medicine 375, no. 24 (2016): 2313-2315, doi: 10.1056/NEJMp1611755.Google Scholar
Gottlieb, S., “From FDA, A Good Framework For Distributing Information on Off-Label Uses,” Health Affairs Blog, April 23, 2008, available at <http://healthaffairs.org/blog/2008/04/23/from-fda-a-good-framework-for-distributing-information-on-off-label-uses/> (last visited May 24, 2018).+(last+visited+May+24,+2018).>Google Scholar
Hey, S.P. and Kesselheim, A.S., “An Unin-formative Truth: The Logic of Amarin’s Off-Label Promotion,” PLoS Medicine 13, no. 3 (2016):e1001978.Google Scholar
Amarin Pharma v US FDA, No. 1:15:cv-03588-PAE, Southern District of New York, August 7, 2016.Google Scholar
Robertson and Kesselheim, supra note 3.Google Scholar
Hey and Kesselheim, supra note 5.Google Scholar
Hey and Kesselheim, supra note 5.Google Scholar
Medical Product Communications, supra note 1.Google Scholar